Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, primarily affecting memory, cognition, and reasoning, ultimately debilitating a person’s ability to perform daily activities. As the most prevalent cause of dementia, AD imposes significant societal and economic burdens worldwide.
Central to the pathophysiology of AD is the accumulation of beta-amyloid (Aβ) peptides, which are implicated in initiating a cascade of molecular events leading to neuronal degeneration.
Understanding the beta-amyloid peptide
Aβ is a peptide derived from the amyloid precursor protein (APP), a transmembrane protein whose cleavage by β-secretase and γ-secretase enzymes generates various Aβ isoforms, predominantly Aβ₄₀ and Aβ₄₂. Although these isoforms differ in length, Aβ₄₂ is particularly prone to aggregation, making it a primary contributor to the pathogenesis of AD.
Aβ peptides, while exhibiting physiological roles such as modulation of synaptic activity and immune defense, become pathological when they accumulate abnormally in the brain. Under typical conditions, Aβ is cleared efficiently through enzymatic degradation and glymphatic drainage. In AD, however, this clearance is impaired owing to age, genetic mutations, and environmental factors, resulting in toxic Aβ accumulation.
The amyloid cascade and the Alzheimer’s disease pathway
The Alzheimer’s disease pathway involves complex molecular mechanisms. The accumulation of Aβ triggers a series of molecular events, beginning with the aggregation of monomeric Aβ into soluble oligomers. These oligomers can subsequently form protofibrils and eventually mature into insoluble amyloid plaques. Although amyloid plaques are a hallmark of AD, it is increasingly recognized that soluble Aβ oligomers are the most neurotoxic species.
Aβ oligomers directly disrupt synaptic transmission and impair long-term potentiation (LTP), which is essential for learning and memory. Their presence has been associated with cognitive deficits even in early-stage AD.
The amyloid cascade hypothesis
Proposed in the 1990s, the amyloid cascade hypothesis posits that Aβ deposition is the initial event in AD pathogenesis, subsequently leading to tau pathology, synaptic dysfunction, and neurodegeneration. The hypothesis is supported by the following key mechanisms:
Synaptic dysfunction: Aβ oligomers interfere with neurotransmitter receptor signaling (including NMDA and AMPA receptors), which impairs calcium signaling and synaptic plasticity, thereby hindering memory consolidation.
Neuroinflammation: The accumulation of Aβ activates microglia and astrocytes, which initially attempt to clear the deposits. However, prolonged activation of these immune cells results in chronic neuroinflammation, exacerbating neuronal damage.
Tau pathology: Aβ deposition precedes the development of neurofibrillary tangles composed of hyperphosphorylated tau protein. These tangles disrupt intracellular transport, further contributing to neuronal loss.
Oxidative stress and mitochondrial dysfunction: Aβ aggregates enhance the production of reactive oxygen species (ROS), which disrupt mitochondrial function, thereby accelerating neuronal damage and cognitive decline.
Genetic and environmental risk factors
Genetic mutations associated with Aβ metabolism are strongly linked to early-onset familial AD. Mutations in the APP, PSEN1, and PSEN2 genes lead to overproduction of Aβ₄₂ and rapid disease progression.
Conversely, sporadic AD, which typically manifests in later life, is influenced by both genetic and environmental factors. The APOE4 allele represents the strongest known genetic risk factor for late-onset AD because it causes impaired Aβ clearance, thereby accelerating its deposition.
Aging itself is the most significant non-genetic risk factor for AD, as the efficiency of endogenous Aβ clearance mechanisms decreases with age. Environmental factors such as poor sleep, cardiovascular health, and suboptimal nutrition also modulate Aβ dynamics and influence brain resilience in the context of aging.
Experimental models
Animal and cellular models, particularly transgenic mice overexpressing mutant human APP, have been of the essence in elucidating the role of Aβ in AD pathology. These models mimic several critical aspects of the disease, including Aβ plaque formation and cognitive deficits, thus facilitating the exploration of the molecular effects of Aβ and the testing of potential therapeutic strategies.
Current and emerging therapeutic strategies
Given the central role of Aβ in AD, it remains a primary target for therapeutic intervention. Several strategies have been explored:
Secretase inhibitors: These compounds aim to reduce Aβ production by inhibiting the enzymes responsible for cleaving APP. Despite initial promise, clinical trials of β- and γ-secretase inhibitors have encountered challenges due to off-target effects and safety concerns.
Immunotherapy: Monoclonal antibodies, such as aducanumab and lecanemab, have been developed to enhance Aβ clearance by targeting the peptide directly. Although some of these therapies have shown modest clinical benefits, their long-term efficacy and safety remain uncertain.
Aggregation inhibitors and degraders: Small molecules that inhibit Aβ aggregation or enhance its degradation through enzymes such as neprilysin and insulin-degrading enzymes are being actively investigated. Although these approaches hold promise, further development and clinical validation are needed.
Gene therapy and nanomedicine: Emerging technologies, such as gene editing and nanoparticle-based drug delivery systems, aim to directly modify Aβ metabolism or enhance its clearance from the brain. These novel strategies are currently in preclinical stages but may offer revolutionary therapeutic avenues in the future.
Recent approvals of anti-Aβ antibodies signify a major step forward in AD therapy. While these treatments remain controversial, they provide proof of concept that reducing the amyloid burden could benefit certain patients, especially in the early stages of the disease.
A broader perspective: Beyond amyloid
Despite the undeniable importance of Aβ in AD research, it is increasingly evident that the disease is multifactorial. Tau protein dysfunction, synaptic loss, mitochondrial impairment, and immune dysregulation all contribute to AD progression. Consequently, combination therapies that address multiple pathological mechanisms are likely to offer the most effective long-term treatment options.
Moreover, the development of advanced biomarkers has enabled the detection of Aβ in cerebrospinal fluid and via positron emission tomography (PET) imaging. These technologies allow for early diagnosis, potentially paving the way for timely intervention and effective management of AD.
Conclusion
Aβ peptides continue to be a cornerstone in AD research, both as critical biomarkers and as therapeutic targets. However, the complexity of AD necessitates a more comprehensive understanding of the underlying pathogenesis. Integrated therapeutic approaches that target multiple aspects of the disease pathway, coupled with early diagnostic techniques, hold the potential to significantly improve outcomes for patients. Ongoing research into Aβ dynamics and its interactions with other disease-modifying factors will be crucial in the development of effective AD treatments.
References
- Hampel, H., Hardy, J., Blennow, K. et al. The Amyloid-β Pathway in Alzheimer’s Disease. Mol Psychiatry 26, 5481–5503 (2021).
- Azargoonjahromi, A. The duality of amyloid-β: its role in normal and Alzheimer’s disease states. Molecular Brain, 17(1), 44 (2024).
- Sun, X., Chen, W. D., & Wang, Y. D. β-Amyloid: the key peptide in the pathogenesis of Alzheimer’s disease. Frontiers in pharmacology, 6, 221 (2015).
- Zhang, Y., Chen, H., Li, R. et al. Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future. Sig Transduct Target Ther 8, 248 (2023).
- Kim, BH., Kim, S., Nam, Y. et al. Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives. Transl Neurodegener 14, 6 (2025).
- Murpy, M., & LeVine III, H. Alzheimer’s disease and the β-amyloid peptide. J Alzheimers Dis, 19(1), 311-323 (2010).
